Moreover, the recent favorable reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm by CMS will likely allow Tempus to aid clinicians in identifying patients at ...

On December 17, the company announced that the Centers for Medicare and Medicaid Services (CMS) will allow reimbursement for assessments of cardiac dysfunction using the Tempus ECG-AF algorithm.

Moreover, the FDA cleared Tempus’ xT CDx. This is a 648-gene tumor profiling test. The FDA also cleared its ECG-AF algorithm, which is used for cardiac risk assessment. CMS followed by approving ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced the national launch of olivia. olivia is an AI-enabled ...